Literature DB >> 12380790

Mycoplasma pneumoniae encephalitis in childhood.

Wen-Chuan Lin1, Ping-Ing Lee, Chun-Yi Lu, Yu-Chia Hsieh, Hsin-Pao Lai, Chin-Yun Lee, Li-Min Huang.   

Abstract

Mycoplasma pneumoniae is an important etiologic agent of acute childhood encephalitis. We retrospectively reviewed 17 cases of M. pneumoniae encephalitis at the Pediatric Department of the National Taiwan University Hospital from April 1997 through March 2000. These cases were diagnosed as having positive immunoglobulin M antibodies (94%), a minimum 4-fold change of complement-fixation antibody titers (47%), or nested polymerase chain reaction. The ages of these patients ranged from 1.5 to 10.9 years (mean, 5.3 years) with a male-to-female ratio of 8:9. The clinical manifestations included fever (94%), altered consciousness (65%), seizure (41%), personality or behavior changes (29%), meningeal sign (24%), visual hallucination (24%), ataxia (12%), Guillain-Barré syndrome (6%), blurred vision (6%), and aphasia (6%). Respiratory symptoms and signs were found in 76% of the patients. Abnormal electroencephalogram and neuroimage were observed in all cases, while abnormal cerebrospinal fluid examination was noted in about one-third of the patients. Five (29%) patients required intensive care because of intractable seizure or respiratory failure. Fourteen (82%) patients recovered completely, but 3 (18%) had sequelae including epilepsy, hydrocephalus, and global neurologic deficits with brain stem dysfunction. In Taiwan, M. pneumoniae should be considered an etiologic pathogen of acute childhood encephalitis if fever and respiratory symptoms and signs are observed with or without abnormal cerebrospinal fluid findings. Supportive treatment is the basis of management.

Entities:  

Mesh:

Year:  2002        PMID: 12380790

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  8 in total

1.  Effects of methylprednisolone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory Mycoplasma pneumoniae pneumonia in children.

Authors:  Li-Shen Shan; Xin Liu; Xin-Yuan Kang; Fei Wang; Xiao-Hua Han; Yun-Xiao Shang
Journal:  World J Pediatr       Date:  2017-01-27       Impact factor: 2.764

2.  Mycoplasma pneumoniae: Innocent Bystander or a True Cause of Central Nervous System Disease?

Authors:  Ari Bitnun; Susan E Richardson
Journal:  Curr Infect Dis Rep       Date:  2010-07       Impact factor: 3.725

Review 3.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

4.  Role of Mycoplasma pneumoniae in pediatric encephalitis.

Authors:  C Domenech; N Leveque; B Lina; F Najioullah; D Floret
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-15       Impact factor: 3.267

5.  Guillain-Barré syndrome and postbariatric surgery polyneuropathies.

Authors:  Kanayochukwu J Aluka; Patricia L Turner; Terrence M Fullum
Journal:  JSLS       Date:  2009 Apr-Jun       Impact factor: 2.172

Review 6.  Mycoplasma pneumoniae-associated mild encephalitis/encephalopathy with a reversible splenial lesion: report of two pediatric cases and a comprehensive literature review.

Authors:  Norishi Ueda; Satoshi Minami; Manabu Akimoto
Journal:  BMC Infect Dis       Date:  2016-11-11       Impact factor: 3.090

7.  Status epilepticus associated with Mycoplasma pneumoniae encephalitis in children: good prognosis following early diagnosis and treatment.

Authors:  Shuo Feng; Jin-Xiao Chen; Ping Zheng; Jian-Zhao Zhang; Zhi-Jie Gao; Ying-Ying Mao; Xin-Na Ji; Shu-Hua Chen; Hong-Mei Sun; Qian Chen
Journal:  Chin Med J (Engl)       Date:  2019-06-20       Impact factor: 2.628

8.  The association between Mycoplasma pneumoniae infection and speech and language impairment: A nationwide population-based study in Taiwan.

Authors:  Ching-Shu Tsai; Vincent Chin-Hung Chen; Yao-Hsu Yang; Tai-Hsin Hung; Mong-Liang Lu; Kuo-You Huang; Michael Gossop
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.